EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial

Martin Langé, Loïc Campion, Luc Ollivier, Marion Renouf, Nicolas Magné, Igor Latorzeff, Pascal Pommier, Etienne Martin, Amaury Paumier, Guillaume Bera, Charles Catton, Jarad Martin und 1 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.01.030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Martin Langé und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology. Electronic address: martin.lange@ico.unicancer.fr. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Conventionally fractionated radiation therapy (CFRT) and hypofractionated RT (HFRT) are established treatments for intermediate-risk (IR) prostate cancer (PCa), with differing dose per fraction. However, their comparative patterns of failure remain unclear. This stuy aims to analyze the distinct relapse patterns of HFRT versus CFRT in terms of local progression-free survival (LPFS), pelvic lymph node metastasis-free survival (pnMFS), extrapelvic lymph node MFS (epnMFS), and bone MFS (bMFS). METHODS AND MATERIALS: Patients with IR PCa included in French and Australian centers in the "PROstate Fractionated Irradiation Trial (PROFIT)" study (NCT00304759), a phase 3, multicenter, randomized controlled trial. Using molecular positron emission tomography imaging, magnetic resonance imaging, and bone scintigraphy, the anatomic sites of relapse were retrospectively identified in biochemically relapsing patients after HFRT or CFRT. LPFS, pnMFS, epnMFS, and bMFS were compared between both treatment arms using Kaplan-Meier analyses. RESULTS AND LIMITATIONS: With a median follow-up of 6.4 years, 274 patients (130 HFRT and 144 CFRT) were included, among whom 35 (24.3%) in the HFRT arm and 28 (19.4%) in the CFRT arm experienced relapse. Median time to relapse varied by site: 4.9 years locally, 3.96 years for pelvic lymph nodes, 2.95 years for extrapelvic lymph nodes, and 3.6 years for bone metastasis. No significant differences were found between HFRT and CFRT arms in LPFS, pnMFS, epnMFS, or bMFS. CONCLUSIONS: Relapse rates after HFRT or CFRT are low, with no discernible variance in anatomical relapse patterns between treatments. Tailored management strategies considering these relapse patterns could optimize care of IR patients, including initial staging and microboosting of dominant lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm Recurrence, LocalHumansMaleAgedMiddle AgedRadiation Dose HypofractionationLymphatic MetastasisDose Fractionation, RadiationProgression-Free SurvivalBone NeoplasmsRetrospective Studies

Autor:innen und Institutionen

  • Department of Radiation Oncology. Electronic address: martin.lange@ico.unicancer.fr.
  • Biostatistics, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), UMR 1232 Inserm-6299 CNRS, Institut de Recherche en Santé de l'Université de Nantes,…
  • Department of Radiation Oncology.
  • Department of Radiation Oncology, Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France.
  • Department of Radiation Oncology, Oncorad Clinique Pasteur, Toulouse, France.
  • Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.

Zitieren

APA

Langé, M., Campion, L., Ollivier, L., Renouf, M., Magné, N., Latorzeff, I., Pommier, P., Martin, E., Paumier, A., Bera, G., Catton, C., Martin, J., & Supiot, S. (2025). Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.01.030

Vancouver

Langé M, Campion L, Ollivier L, Renouf M, Magné N, Latorzeff I, et al. Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.01.030

BibTeX
@article{Lang2025,
  author = {Langé, Martin and Campion, Loïc and Ollivier, Luc and Renouf, Marion and Magné, Nicolas and Latorzeff, Igor and Pommier, Pascal and Martin, Etienne and Paumier, Amaury and Bera, Guillaume and Catton, Charles and Martin, Jarad and Supiot, Stephane},
  title = {Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.01.030}
}
Kostenlos starten →